Association between pioglitazone use and head and neck cancer: Population-based case-control study

Tzong Hann Yang, Sudha Xirasagar, Yen Fu Cheng, Chuan Song Wu, Yi Wei Kao, Ben Chang Shia, Herng Ching Lin

Research output: Contribution to journalArticle

Abstract

Background: This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer. Methods: Data for this case-control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis. Results: Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3% vs 18.5%, P <.001) was observed. Multiple regression analysis showed adjusted odds of pioglitazone use of 1.06 (95% CI: 1.02-1.10) among cases relative to controls. Conclusions: Prior pioglitazone use was associated with oral cavity cancer.

Original languageEnglish
JournalHead and Neck
DOIs
Publication statusAccepted/In press - Jan 1 2019

Keywords

  • diabetes
  • epidemiology
  • head and neck cancer
  • oral cavity cancer
  • pioglitazone

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Association between pioglitazone use and head and neck cancer : Population-based case-control study. / Yang, Tzong Hann; Xirasagar, Sudha; Cheng, Yen Fu; Wu, Chuan Song; Kao, Yi Wei; Shia, Ben Chang; Lin, Herng Ching.

In: Head and Neck, 01.01.2019.

Research output: Contribution to journalArticle

@article{b3443ebabcb44493909c19d874db15d5,
title = "Association between pioglitazone use and head and neck cancer: Population-based case-control study",
abstract = "Background: This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer. Methods: Data for this case-control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis. Results: Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3{\%} vs 18.5{\%}, P <.001) was observed. Multiple regression analysis showed adjusted odds of pioglitazone use of 1.06 (95{\%} CI: 1.02-1.10) among cases relative to controls. Conclusions: Prior pioglitazone use was associated with oral cavity cancer.",
keywords = "diabetes, epidemiology, head and neck cancer, oral cavity cancer, pioglitazone",
author = "Yang, {Tzong Hann} and Sudha Xirasagar and Cheng, {Yen Fu} and Wu, {Chuan Song} and Kao, {Yi Wei} and Shia, {Ben Chang} and Lin, {Herng Ching}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/hed.26046",
language = "English",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Association between pioglitazone use and head and neck cancer

T2 - Population-based case-control study

AU - Yang, Tzong Hann

AU - Xirasagar, Sudha

AU - Cheng, Yen Fu

AU - Wu, Chuan Song

AU - Kao, Yi Wei

AU - Shia, Ben Chang

AU - Lin, Herng Ching

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer. Methods: Data for this case-control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis. Results: Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3% vs 18.5%, P <.001) was observed. Multiple regression analysis showed adjusted odds of pioglitazone use of 1.06 (95% CI: 1.02-1.10) among cases relative to controls. Conclusions: Prior pioglitazone use was associated with oral cavity cancer.

AB - Background: This study aimed to evaluate the association between pioglitazone use and the occurrence of head and neck cancer. Methods: Data for this case-control study were retrieved from the Taiwan National Health Insurance Research Database. A total of 21 464 diabetic patients newly diagnosed with head and neck cancers were identified. We used propensity score matching to select 64 392 comparison patients (3:1 ratio). Multiple logistic regression modeling was used to examine the association of head and neck cancer with pioglitazone use in the 5 years preceding the cancer diagnosis. Results: Bivariate analysis showed a significant difference in the prevalence of prior using pioglitazone between cases and controls (19.3% vs 18.5%, P <.001) was observed. Multiple regression analysis showed adjusted odds of pioglitazone use of 1.06 (95% CI: 1.02-1.10) among cases relative to controls. Conclusions: Prior pioglitazone use was associated with oral cavity cancer.

KW - diabetes

KW - epidemiology

KW - head and neck cancer

KW - oral cavity cancer

KW - pioglitazone

UR - http://www.scopus.com/inward/record.url?scp=85076381118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076381118&partnerID=8YFLogxK

U2 - 10.1002/hed.26046

DO - 10.1002/hed.26046

M3 - Article

AN - SCOPUS:85076381118

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

ER -